In vitro antileishmanial activity of nicotinamide.
Our study represents the first report demonstrating the antileishmanial activity of nicotinamide (NAm), a form of vitamin B(3). A 5 mM concentration of NAm significantly inhibited the intracellular growth of Leishmania amastigotes and the NAD-dependent deacetylase activity carried by parasites overexpressing Leishmania major SIR2 (LmSIR2). However, the transgenic parasites were as susceptible as the wild-type parasites to NAm-induced cell growth arrest. Therefore, we conclude that NAm inhibits leishmanial growth and that overexpression of LmSIR2 does not overcome this inhibition. The mechanism of the inhibition is not defined but may include other in vivo targets. NAm may thus represent a new antileishmanial agent which could potentially be used in combination with other drugs during therapy.
Sereno
D
D
U R008, Pathogénie des Trypanosomatidés, Centre IRD de Montpellier, Montpellier, France. sereno@mpl.ird.fr
Alegre
A Monte
AM
Silvestre
R
R
Vergnes
B
B
Ouaissi
A
A
D000818:Animals; D000981:Antiprotozoal Agents; D004358:Drug Therapy; D018320:Leishmania major / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D009536:Niacinamide / Q000494:pharmacology*; D010957:Plasmids; D037761:Sirtuins / Q000235:genetics
D000981:Antiprotozoal Agents; D009536:Niacinamide; D037761:Sirtuins